전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved188 programs
CGTAAVLimited DatastaleMark TuszynskiPhase 1

AAV2-BDNF Gene Therapy (AAV2-BDNF Gene Therapy)

Alzheimer's Disease; Mild Cognitive Impairment · Alzheimer's Disease

#AlzheimersDisease#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 (AAV2-hAQP1)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 1 (AAV2-hAQP1 Concentration 1)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 2 (AAV2-hAQP1 Concentration 2)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 3 (AAV2-hAQP1 Concentration 3)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 4 (AAV2-hAQP1 Concentration 4)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleCelosia Therapeutics Pty LtdPhase 1

AAV9 Gene therapy (AAV9 Gene therapy)

ALS (Amyotrophic Lateral Sclerosis) · ALS (Amyotrophic Lateral Sclerosis)

#ALSAmyotrophicLateralSclerosis#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTAAVLimited DatastaleUnlimited Biotechnology LLCPhase 2

AAV9-Follistatin gene therapy (AAV9-Follistatin gene therapy)

Age-related Muscle Decline · Age-related Muscle Decline

#Age-relatedMuscleDecline#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTAAVLimited DatastaleEmily de los ReyesPhase 2

AAV9.SLC6A1 Gene Therapy (AAV9.SLC6A1 Gene Therapy)

SLC6A1 · SLC6A1

#SLC6A1#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleAskBio France, SAS, a subsidiar…Phase 2

AB-1001 Gene Therapy (AB-1001 Gene Therapy)

Huntington Disease · Huntington Disease

#HuntingtonDisease#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleCandel Therapeutics, Inc.Phase 2

ADV-TK (ADV-TK, adenovirus-thymidine kinase enzyme, ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy)

Hepatocellular Carcinoma; Liver Transplantation · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastalePeking Union Medical CollegePhase 2

trastuzumab (Herceptin, AR,AR antagonist ++ goserelin + pertuzumab + trastuzumab)

Salivary Gland Carcinoma; Precision Therapy · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#Antibody#Phase2#monoclonal-antibody#PrecisionTherapy+1
Trials 1Status Recruiting
CGTLimited DatastaleAutolus LimitedPhase 2

AUTO CAR T cell therapy (AUTO CAR T cell therapy)

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy; Multiple Myeloma · Patients Followed for up to 15 Years Fol

#PatientsFollowedforupto15YearsFo#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

Adebrelimab + Cetuximab+ Chemotherapy (Adebrelimab + Cetuximab+ Chemotherapy)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
CGTLimited DatastaleShanghai Cell Therapy Research …Phase 2

Anti-CTLA-4/PD-1 expressing MUC1-CAR-T (Anti-CTLA-4/PD-1 expressing MUC1-CAR-T)

Advanced Solid Tumor · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleRochePhase 1

atezolizumab (Tecentriq, Atezolizumab and Interleukin-12 Gene Therapy)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
CGTLimited DatastaleLuminary TherapeuticsPhase 1

Autologous CAR-T cell therapy expressing the BAFF-ligand. (Autologous CAR-T cell therapy expressing the BAFF-ligand.)

Multiple Myeloma, Refractory; Multiple Myeloma in Relapse · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastalePeking University People's Hosp…Phase 2

BCMA-CD19 CAR-T therapy (BCMA-CD19 CAR-T therapy)

Systemic Lupus Erythematosus; Inflammatory Myopathy · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleHebei Yanda Ludaopei HospitalPhase 1

BCMA/CD19 dual-target CAR-T cell immunotherapy (BCMA/CD19 dual-target CAR-T cell immunotherapy)

Multiple Myeloma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleXinqiao Hospital of ChongqingPhase 2

Benmelstobart combined with Bevacizumab and chemotherapy (Benmelstobart combined with Bevacizumab and chemotherapy)

NSCLC Stage IV Without EGFR/ALK Mutation · EGFR

#EGFR#Antibody#Phase2#monoclonal-antibody#NSCLCStageIVWithoutEGFR+2
Trials 1Status Recruiting

4 / 10 pages

← PreviousNext →